• Skip to main content
  • Skip to header right navigation
  • Skip to site footer

Log in
  • Search
    • Search All SAGES Content
    • Search SAGES Guidelines
    • Search the Video Library
    • Search the Image Library
    • Search the Abstracts Archive
www.sages.org

SAGES

Reimagining surgical care for a healthier world

  • Home
    • Search
    • SAGES Home
    • SAGES Foundation Home
  • About
    • Awards
    • Who Is SAGES?
    • Leadership
    • Our Mission
    • Advocacy
    • Committees
      • SAGES Board of Governors
      • Officers and Representatives of the Society
      • Committee Chairs and Co-Chairs
      • Committee Rosters
      • SAGES Past Presidents
  • Meetings
    • SAGES NBT Innovation Weekend
    • SAGES Annual Meeting
      • 2026 Scientific Session Call for Abstracts
      • 2026 Emerging Technology Call for Abstracts
    • CME Claim Form
    • SAGES Past, Present, Future, and Related Meeting Information
    • SAGES Related Meetings & Events Calendar
  • Join SAGES!
    • Membership Application
    • Membership Benefits
    • Membership Types
      • Requirements and Applications for Active Membership in SAGES
      • Requirements and Applications for Affiliate Membership in SAGES
      • Requirements and Applications for Associate Active Membership in SAGES
      • Requirements and Applications for Candidate Membership in SAGES
      • Requirements and Applications for International Membership in SAGES
      • Requirements for Medical Student Membership
    • Member Spotlight
    • Give the Gift of SAGES Membership
  • Patients
    • Join the SAGES Patient Partner Network (PPN)
    • Patient Information Brochures
    • Healthy Sooner – Patient Information for Minimally Invasive Surgery
    • Choosing Wisely – An Initiative of the ABIM Foundation
    • All in the Recovery: Colorectal Cancer Alliance
    • Find A SAGES Surgeon
  • Publications
    • Sustainability in Surgical Practice
    • SAGES Stories Podcast
    • Patient Information Brochures
    • Patient Information From SAGES
    • TAVAC – Technology and Value Assessments
    • Surgical Endoscopy and Other Journal Information
    • SAGES Manuals
    • MesSAGES – The SAGES Newsletter
    • COVID-19 Archive
    • Troubleshooting Guides
  • Education
    • Wellness Resources – You Are Not Alone
    • Avoid Opiates After Surgery
    • SAGES Subscription Catalog
    • SAGES TV: Home of SAGES Surgical Videos
    • The SAGES Safe Cholecystectomy Program
    • Masters Program
    • Resident and Fellow Opportunities
      • MIS Fellows Course
      • SAGES Robotics Residents and Fellows Courses
      • SAGES Free Resident Webinar Series
      • Fluorescence-Guided Surgery Course for Fellows
      • Fellows’ Career Development Course
    • SAGES S.M.A.R.T. Enhanced Recovery Program
    • SAGES @ Cine-Med Products
      • SAGES Top 21 Minimally Invasive Procedures Every Practicing Surgeon Should Know
      • SAGES Pearls Step-by-Step
      • SAGES Flexible Endoscopy 101
    • SAGES OR SAFETY Video Activity
  • Opportunities
    • Fellowship Recognition Opportunities
    • SAGES Advanced Flexible Endoscopy Area of Concentrated Training (ACT) SEAL
    • Multi-Society Foregut Fellowship Certification
    • Research Opportunities
    • FLS
    • FES
    • FUSE
    • Jobs Board
    • SAGES Go Global: Global Affairs and Humanitarian Efforts
  • OWLS/FLS
You are here: Home / Abstracts / LONG-TERM IMPACT OF SLEEVE GASTRECTOMY AND ROUX-EN-Y GASTRIC BYPASS ON BIOPSY-PROVEN NON-ALCOHOLIC FATTY LIVER DISEASE

LONG-TERM IMPACT OF SLEEVE GASTRECTOMY AND ROUX-EN-Y GASTRIC BYPASS ON BIOPSY-PROVEN NON-ALCOHOLIC FATTY LIVER DISEASE

Deepa V Cherla, MD1, Noe A Rodriguez, MD2, Maryna Chumakova-Orin, MD1, Tavankit Singh1, Arthur J Mccullough1, Stacy A Brethauer1, Philip R Schauer1, Ali Aminian, MD1. 1Cleveland Clinic Foundation, 2Florida Atlantic University

INTRODUCTION: Our aim was to study the long-term effects of sleeve gastrectomy (SG) and Roux-en-Y gastric bypass on Non-alcoholic fatty liver disease (NAFLD)/steatohepatitis (NASH).  NAFLD/NASH is considered the hepatic manifestation of metabolic syndrome and is closely associated with obesity, insulin resistance, diabetes, and dyslipidemia.

METHODS: During an eight year period (2008-2015), 3,813 patients had simultaneous liver biopsy at the time of primary RYGB and SG at an academic center. Utilizing very strict inclusion criteria, we identified 487 patients with biopsy-proven NAFLD or NASH who had abnormal alanine aminotransferase (ALT) or aspartate aminotransferase (AST) values (≥40 IU/L) at baseline. Matching of SG to RYGB patients (1:4 ratio) was performed via logistic regression and propensity scores adjusting for age, gender, BMI, presence of diabetes, NAFLD activity score (NAS), presence of NASH, and fibrosis score. Changes in liver function tests (LFTs) at least one year after surgery were compared to baseline values and between the surgical groups.

RESULTS: A total of 310 (weighted) patients (SG n=62, and RYGB n=248) with a median follow-up time of 4 years (range, 1-10) were included in the analysis. The distribution of covariates was well-balanced after propensity matching. The NAS (3.7±1.5 versus 3.6±1.5, p=0.68), presence of NASH (65% versus 59%, p=0.42), and fibrosis score (1.1±1.0 versus 1.1±1.2, p=0.92) were comparable between SG and RYGB groups, respectively. In a majority of patients, LFT values normalized after bariatric surgery (83% at 1-year and 84% at the last follow-up time). The proportions of patients having normalized LFT values did not differ significantly between the SG and RYGB groups at either the 1-year or long-term time points. The AST decreased from (SG: 49.1±21.5 versus RYGB 49.3±22.0, p=0.92) at baseline to (SG: 26.8±10.2 versus RYGB: 24.9±9.8, p=0.27) at 1-year and to (SG: 28.0±16.5 versus RYGB: 26.5±15.5, p=0.33) at the last follow-up. Similarly, a significant reduction in ALT values from (SG: 61.7±30.0 versus RYGB 59.4±24.9, p=0.75) at baseline to (SG: 28.5±15.8 versus RYGB: 26.6±14.3, p=0.49) at 1-year and to (SG: 27.2±21.5 versus RYGB: 26.1±19.2, p=0.52) at the last follow-up was observed.

CONCLUSIONS: In patients with biopsy-proven NAFLD/NASH, abnormal LFTs are normalized in the large majority of SG and RYGB patients by the end of the first year post-surgery. This study, which is the largest reported comparative series, also provides evidence that, after controlling for baseline clinical and biopsy-proven pathological variables, both procedures are similarly effective in improving liver function.


Presented at the SAGES 2017 Annual Meeting in Houston, TX.

Abstract ID: 95353

Program Number: S124

Presentation Session: Bariatric IV – Quality and Outcomes

Presentation Type: Podium

102

Share this:

  • Click to share on X (Opens in new window) X
  • Click to share on Facebook (Opens in new window) Facebook
  • Click to share on LinkedIn (Opens in new window) LinkedIn
  • Click to share on Pinterest (Opens in new window) Pinterest
  • Click to share on WhatsApp (Opens in new window) WhatsApp
  • Click to share on Reddit (Opens in new window) Reddit
  • Click to share on Pocket (Opens in new window) Pocket
  • Click to share on Mastodon (Opens in new window) Mastodon
  • Click to share on Threads (Opens in new window) Threads
  • Click to share on Bluesky (Opens in new window) Bluesky

Related


sages_adbutler_leaderboard

Hours & Info

11300 West Olympic Blvd, Suite 600
Los Angeles, CA 90064

1-310-437-0544

[email protected]

Monday – Friday
8am to 5pm Pacific Time

Find Us Around the Web!

  • Bluesky
  • X
  • Instagram
  • Facebook
  • YouTube

Copyright © 2025 · SAGES · All Rights Reserved

Important Links

Healthy Sooner: Patient Information

SAGES Guidelines, Statements, & Standards of Practice

SAGES Manuals